Drugmaker GSK PLC won’t have to answer a securities fraud class action stemming from its concealment of a link between Zantac and a cancer-causing substance because it was filed too late.

British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, respiratory and cancer treatments as it recovered from costly US lawsuits over ...